BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

New BD Neopak 2.25 mL Prefillable Glass Syringe Helps Improve Safety and Convenience for Patients

Dec 15, 2016

FRANKLIN LAKES, N.J., DEC. 15, 2016 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Neopak 2.25 mL prefillable glass syringe, specifically designed for biopharmaceutical manufacturers that develop, manufacture and market high-value and sensitive biologic drugs that require higher quality levels and performance to treat chronic diseases such as, rheumatoid arthritis, psoriasis, lupus and severe asthma.

"Through our continued investment in innovation, this new syringe enables biopharmaceutical manufacturers to develop drug-syringe combination products with extended injection intervals. This will provide patients with more time between injections and decrease the frequency of injections," said Peter Nolan, worldwide president of Pharmaceutical Systems for BD. "By offering higher volume subcutaneous injections, the BD Neopak 2.25 mL prefillable glass syringe is designed to help reduce the number of necessary injections, aiming to improve the safety and convenience for patients."

Built on the legacy of BD's most advanced biotech syringe platform, the BD Neopak 2.25 mL glass prefillable syringe is designed to reduce undesired interactions, such as drug degradation or aggregation between the primary container and drug, to support biopharmaceutical manufacturers' efforts to mitigate product development and commercialization risks. The new syringe is now commercially available in the United States, Europe and Japan.

BD is a leading partner for biopharmaceutical manufacturers offering a wide range of services to assess drug-container compatibility, evaluate system-related functional requirements, human factors and provide regulatory expertise to support drug development. The BD Neopak 2.25 mL glass prefillable syringe expands the BD Neopak portfolio, which also includes a BD Neopak 1 mL glass prefillable syringe.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

For more information on BD, please visit

Matthew Coppola

201 847 7370

Monique N. Dolecki

201 847 5378

Back to News Releases

Please note, products and services mentioned may not be licensed/available in Canada. Please check with your local BD representative.


This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.